The efficacy of crizotinib combined with standard chemotherapy for ALK-mutant HR-NB is currently being evaluated in a COG Phase III trial (NCT03126916).Owing to the limitations of the first-generation ALK inhibitors, such as crizotinib, novel drugs, such as Ceritinib, Entrectinib and Lorlatinib, have been designed [43,44,45,46]. The gene discussed is ALK; the disease is neuroblastoma.